Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis
NCT ID: NCT00995449
Last Updated: 2014-06-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
9 participants
INTERVENTIONAL
2010-01-31
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis
NCT06906549
A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)
NCT00299546
A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201
NCT00831649
A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis
NCT00443651
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
NCT01999192
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
KB003 70 mg
KB003
KB003 IV x5 doses
KB003 200 mg
KB003
KB003 IV x5 doses
KB003 600 mg
KB003
KB003 IV x5 doses
Placebo
Placebo Comparator
Placebo IV x5 doses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KB003
KB003 IV x5 doses
Placebo Comparator
Placebo IV x5 doses
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* C-reactive Protein (CRP) \> Upper Limit Normal (ULN)
* Prior inadequate response from biologic therapy
* Stable regimens of concomitant RA therapies
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Humanigen, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nestor A. Molfino, MD, MSC
Role: STUDY_CHAIR
Humanigen, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford, California, United States
Westlake Village, California, United States
Miami, Florida, United States
Honolulu, Hawaii, United States
Frederick, Maryland, United States
Wheaton, Maryland, United States
St Louis, Missouri, United States
St Louis, Missouri, United States
Wilmington, North Carolina, United States
Tulsa, Oklahoma, United States
Oak Creek, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KB003-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.